Objective: Medication related osteonecrosis of the jaw (MRONJ) is a major complication of treatment with antiresorptive and antiangiogenic agents in the oral and maxillofacial region. This cross-sectional study aims to evaluate knowledge and awareness about MRONJ among dentists working in Ankara, Turkey. Material and Methods: A cross-sectional survey was carried out among dentists working at public oral and dental health care centers in Ankara. A questionnaire was designed to seek information about dentists' demographic characteristics, their knowledge of the term 'MRONJ', of drugs that cause jaw osteonecrosis, of the risk factors of MRONJ and their attitudes and practices regarding MRONJ. A total of 325 dentists participated in the study. Results: More than half of the dentists in this study were unable to define osteonecrosis of the jaw. Most (61.2%) were able to identify bisphosphonates associated with MRONJ, but about 80% were unaware of antiangiogenic drugs and 93.5% of nuclear factor kappa B ligand inhibitors. Most dentists in the study were unaware of most of the main risk factors for MRONJ. Thirty-six percent of the dentists had received MRONJ training during their undergraduate education, but only 5.2% had been trained in the last five years. Conclusion: This study highlights a huge lack of knowledge and awareness about MRONJ among dentists in Turkey. There is a need to provide further education and training in order to improve dentists' awareness of bisphosphonates and other medications that have the potential to cause osteonecrosis. Education of healthcare professionals and multidisciplinary cooperation can potentially improve patient safety and reduce the risk of developing MRONJ.
Keywords: Medication related osteonecrosis of the jaw; antiresorptive drugs; antiangiogenic drugs; dentists
Amaç: Çenenin ilaca bağlı osteonekrozu (MRONJ), oral ve maksillofasiyal bölgede antirezorptif ve antianjiyojenik ajanlarla tedavinin önemli bir komplikasyonudur. Bu kesitsel çalışma Türkiye, Ankara'daki diş hekimleri arasındaki MRONJ bilgi ve farkındalığını değerlendirmeyi amaçlamaktadır. Gereç ve Yöntemler: Ankara'da, kamu ağız ve diş sağlığı merkezlerinde çalışan diş hekimleri arasında kesitsel bir anket yapılmıştır. Diş hekimlerinin demografik özellikleri, 'MRONJ' terimi, çene osteonekrozuna neden olan ilaçlar, MRONJ risk faktörleri, MRONJ ile ilgili tutum ve uygulamaları hakkında bilgi edinmek amacıyla bir anket tasarlanmıştır. Çalışmaya, toplam 325 diş hekimi katılmıştır. Bulgular: Bu çalışmada, diş hekimlerinin yarısından fazlası çenenin osteonekrozunu tanımlayamamıştır. Çoğu (%61,2) MRONJ ile ilişkili bifosfonatları tanımlayabilmiştir, ancak yaklaşık %80'i antianjiyojenik ilaçlardan ve %93,5'i nükleer faktör kappa B ligand inhibitörlerinden habersizdi. Çalışmada çoğu diş hekimi, MRONJ için ana risk faktörlerinin çoğunun farkında değildi. Diş hekimlerinin %36'sı lisans eğitimi sırasında MRONJ eğitimi almıştır, ancak son 5 yılda sadece %5,2'si eğitim almıştır. Sonuç: Bu çalışma, Türkiye'deki diş hekimleri arasında MRONJ hakkında büyük bir bilgi ve farkındalık eksikliğini vurgulamaktadır. Diş hekimlerinin, bisfosfonatlar ve çene nekrozuna neden olma potansiyeli olan diğer ilaçlarla ilgili farkındalıklarını artırmak için daha fazla eğitim ve öğretime ihtiyaç vardır. Sağlık profesyonellerinin eğitimi ve multidisipliner iş birliği potansiyel olarak hasta güvenliğini artırabilir ve MRONJ gelişme riskini azaltabilir.
Anahtar Kelimeler: Çenenin ilaçlarla ilişkili osteonekrozu; antiresorptif ilaçlar; antianjiyogenik ilaçlar; diş hekimleri
- Nakatsuka K. [Development of bisphosphonates]. Nihon Rinsho. 2003;61(2):219-25.[PubMed]
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7.[Crossref] [PubMed]
- Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(1):14-21.[Crossref] [PubMed]
- Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc. 2005;136(12):1675-81.[Crossref] [PubMed]
- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527-34.[Crossref] [PubMed]
- Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.[Crossref] [PubMed] [PMC]
- Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76(3):209-11.[Crossref] [PubMed]
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56. Erratum in: J Oral Maxillofac Surg. 2015;73(7):1440. Erratum in: J Oral Maxillofac Surg. 2015;73(9):1879.[Crossref] [PubMed]
- Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ. 2005;21;172(13):1684.[Crossref] [PubMed] [PMC]
- Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;1;48(4):677-92.[Crossref] [PubMed]
- Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-19.[Crossref] [PubMed]
- Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 ;19(6):733-59.[Crossref] [PubMed]
- Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(5 Suppl):61-70.[Crossref] [PubMed]
- Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218:62-79.[Crossref] [PubMed] [PMC]
- Bernardi S, Di Girolamo M, Necozione S, Continenza MA, Cutilli T. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience. Musculoskelet Surg. 2019;103(1):47-53.[Crossref] [PubMed]
- Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw. Dental Clinical Guidance. 2017.[Link]
- Sturrock A, Preshaw PM, Hayes C, Wilkes S. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open. 2019;3;9(3):e024376.[Crossref] [PubMed] [PMC]
- Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine. European Medicines Agency. Accessed December 27, 2019.[Link]
- Oral health management of patients at risk of medication-related osteonecrosis of the jaw. Accessed December 27, 2019.[Link]
- Sturrock A, Preshaw PM, Hayes C, Wilkes S. General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England. BMJ Open. 2019;17;9(6):e029951.[Crossref] [PubMed] [PMC]
- Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117-20.[Crossref] [PubMed]
- Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol. 2012;23(1):193-200.[Crossref] [PubMed]
- El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc. 2017;148(8):584-94.e2.[Crossref] [PubMed]
- Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011;47(3):191-4.[Crossref] [PubMed]
- Yoo JY, Park YD, Kwon YD, Kim DY, Ohe JY. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws. J Investig Clin Dent. 2010;1(2):90-5.[Crossref] [PubMed]
- Conte-Neto N, Bastos AS, Spolidorio LC, Marcantonio RA, Marcantonio E Jr. Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head Face Med. 2011;27;7:7.[Crossref] [PubMed] [PMC]
- Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metabol. 2010;54(2):206-12.[Crossref] [PubMed]
- López-Jornet P, Camacho-Alonso F, Molina-Mi-ano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract. 2010;16(5):878-82.[Crossref] [PubMed]
- Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg. 2015;73(6):1095-105.[Crossref] [PubMed]
- Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J. 2017;27;222(2):121-5.[Crossref] [PubMed]
- Escobedo M, García-Consuegra L, Junquera S, Olay S, Ascani G, Junquera L, et al. Medication-related osteonecrosis of the jaw: a survey of knowledge, attitudes, and practices among dentists in the principality of Asturias (Spain). J Stomatol Oral Maxillofac Surg. 2018;119(5):395-400.[Crossref] [PubMed]
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.[Crossref] [PubMed]
- Vinitzky-Brener I, Ibá-ez-Mancera NG, Aguilar-Rojas AM, Álvarez-Jardón AP. Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists. Med Oral Patol Oral Cir Bucal. 2017;1;22(1):e84-e7.[PubMed] [PMC]
- de Lima PB, Brasil VL, de Castro JF, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer. 2015;23(12):3421-6.[Crossref] [PubMed]
- Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S, et al. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg. 2012;40(3):277-82.[Crossref] [PubMed]
- Masson DR, Callaghan EO, Seager M. The knowledge and attitudes of north wales healthcare professionals to bisphosphonate associated osteochemonecrosis of the jaws. Journal of Disability and Oral Health. 2009;10(4):175-83.[Link]
.: Process List